公开(公告)号：US11866414B2

公开(公告)日：2024-01-09

申请号：US17743557

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Zili Xiao

IPC: C07D249/04 ,  A61P25/28 ,  A61P25/16 ,  A61K31/501

CPC classification number: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20220388987A1

公开(公告)日：2022-12-08

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240124421A1

公开(公告)日：2024-04-18

申请号：US18539519

申请日：2023-12-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20250163004A1

公开(公告)日：2025-05-22

申请号：US18976869

申请日：2024-12-11

Applicant: Bristol-Myers Squibb Company

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240190829A1

公开(公告)日：2024-06-13

申请号：US18524426

申请日：2023-11-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

CPC classification number: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US11884650B2

公开(公告)日：2024-01-30

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20220411384A1

公开(公告)日：2022-12-29

申请号：US17743557

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61P25/16 ,  A61K31/501 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.